-

Savara to Participate in Three Upcoming Investor Conferences

Jefferies London Healthcare Conference

Piper Sandler 34th Annual Healthcare Conference

Evercore ISI 5th Annual HealthCONx Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate at the following investor healthcare conferences:

Jefferies London Healthcare Conference
November 16, 2022 at 9:35am PT/ 12:35pm ET / 5:35pm GMT
Corporate Presentation
Waldorf Hilton, London, UK

Piper Sandler 34th Annual Healthcare Conference
November 29, 2022 at 5:00am PT / 8:00am ET
Corporate Presentation
Lotte New York Palace, New York City, NY

Evercore ISI 5th Annual HealthCONx Conference
November 30, 2022 at 10:50am PT / 1:50pm ET
Fireside Chat
Virtual Conference

A webcast of each presentation will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366

Industry:

Savara Inc.

NASDAQ:SVRA
Release Versions
English

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366

More News From Savara Inc.

Savara Reports First Quarter Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and provided a business update. "With approximately $203 million in cash and, upon MOLBREEVI approval, access to up to an additional $150 million in non-dilutive capital through debt and royalty structures, we remain well capitalized to fund global commercial launch prepa...

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on Tuesday, May 19th at 10:00am ET in New York, NY at the NASDAQ headquarters. The live webcast and subsequent replay will be available on the “Events & Presentations” sectio...

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to 24 new employees who recently joined the Company. The inducement awards consist of options to purchase 18,500 shares of the Company’s common stock, restricted stock units (RSUs) cove...
Back to Newsroom